“We believe these data are extremely compelling and highlight the potentially meaningful benefits of early detection of Candida with our T2Candida Panel, including significantly reducing hospital costs and, more importantly, saving so many patient lives,” said T2 Biosystems CEO John McDonough. “The findings from this study support our goal of changing the paradigm in sepsis diagnosis, and we look forward to the opportunity to help implement this important change for patients, physicians and hospital administrators.”